Upgrade to SI Premium - Free Trial

Amgen's (AMGN) ESMO Update is a Net Positive - Credit Suisse

September 21, 2020 6:45 AM
Credit Suisse analyst Evan Seigerman reiterated an Outperform rating and $290.00 price target on Amgen (NASDAQ: AMGN) after the company ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments